The role of anticoagulation clinics in the era of new oral anticoagulants

Sophie Testa, Oriana Paoletti, Anke Zimmermann, Laura Bassi, Silvia Zambelli, Emilia Cancellieri, Sophie Testa, Oriana Paoletti, Anke Zimmermann, Laura Bassi, Silvia Zambelli, Emilia Cancellieri

Abstract

Anticoagulation Clinics (ACs) are services specialized in management of patients on anticoagulant treatment. At present, ACs manage patients chiefly on antivitamin K antagonists (AVKs), but patient population has already changed in the last few years, because of an increase of treatments with other anticoagulant drugs, which require different management systems. The strong increase in the number of patients at AC, mainly on long-term treatment, has determined the development of web management, through telemedicine systems, improving the quality of life and maintaining the same clinical quality levels. New oral anticoagulants (NOAs) have shown to be as effective as AVK antagonists in stroke prevention in atrial fibrillation and for treatment of venous thromboembolism in addition to VTE prophylaxis in orthopaedic surgery, when administered at a fixed dose, but patient adherence and compliance are crucial for good quality treatment. At present, lacking data from the real world, an oversimplification of treatment with NOAs could cause unjustified risks for patients and also a possible future underuse of good drugs. For these reasons the vigilance must be high and ACs can have a crucial role in defining which is the best management for NOA patients and how to do it, as it happened for AVKs.

References

    1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6):160S–198S.
    1. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Lancet. 1996;348(9025):423–428.
    1. Palareti G, Manotti C, D’Angelo A, et al. Thrombotic events during oral anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study. Thrombosis and Haemostasis. 1997;78(6):1438–1443.
    1. Bussey HI, Rospond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy. 1989;9(4):214–219.
    1. Bussey HI, Chiquette E, Amato MG. Anticoagulation clinic care versus routine medical care: a review and interim report. Journal of Thrombosis and Thrombolysis. 1996;2:315–319.
    1. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Archives of Internal Medicine. 1998;158(15):1641–1647.
    1. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000;356(9224):97–102.
    1. Elston-Lafata J, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. Journal of General Internal Medicine. 2000;15(1):31–37.
    1. Fitzmaurice DA, Gardiner C, Kitchen S, Mackie I, Murray ET, Machin SJ. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. British Journal of Haematology. 2005;131(2):156–165.
    1. Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. British Medical Journal. 2005;331(7524):1057–1059.
    1. Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database of Systematic Reviews. 2010;4CD003839
    1. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. New England Journal of Medicine. 2010;363(17):1608–1620.
    1. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379(9813):322–334.
    1. Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H. Can oral anticoagulation be managed using telemedicine and patient self-testing? A pilot study. Clinical and Laboratory Haematology. 2006;28(2):122–125.
    1. Testa S, Alatri A, Paoletti O, et al. Reorganisation of an anticoagulation clinic using a telemedicine system: Description of the model and preliminary results. Internal and Emergency Medicine. 2006;1(1):24–29.
    1. Testa S, Paoletti O, Zimmermann A, Bassi L, Cancellieri E. Telemedicine for managing patients on oral anticoagulant therapy. Telemedicine Techniques and Applications. 2011;15:331–346.
    1. Eikelboom JW, Weitz JI. Update on antithrombotic therapy: new anticoagulants. Circulation. 2010;121(13):1523–1532.
    1. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics. 2009;48(1):1–22.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–1151.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine. 2011;365:883–891.
    1. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2011;365:981–992.
    1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, supplement):e419S–e494S.
    1. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, supplement):e278S–e325S.
    1. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thrombosis and Haemostasis. 2011;106(5):868–876.
    1. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. American Journal of Hematology. 2010;85(3):185–187.
    1. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate2012. Thrombosis and Haemostasis. 107(5):985–997.
    1. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clinical Chemistry and Laboratory Medicine. 2011;49(5):761–772.
    1. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. American Journal of Hypertension. 2006;19(11):1190–1196.
    1. Newby LK, Allen LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–212.
    1. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. The Annals of Pharmacotherapy. 2012;46(4, article e10)
    1. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. The American Journal of Geriatric Pharmacotherapy. 2012;10(2):160–163.
    1. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran) Spine. 2012;37(14):E863–E865.
    1. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Archives of Internal Medicine. 2011;171(14):1285–1286.
    1. Fieland D, Taylor M. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. The Annals of Pharmacotherapy. 2012;46(article e3)(1)
    1. Boland M, Murphy M, Murphy M, McDermott E. Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report. Journal of Medical Case Reports. 2012;6(1) article 129
    1. Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica. 2002;87(10):1081–1086.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel